Pune, Aug. 18, 2020 (GLOBE NEWSWIRE) -- The global recombinant vaccines market size is expected to reach USD 25.32 billion by 2027, exhibiting a CAGR of 11.3% between 2019 to 2027. The introduction of innovative recombinant vaccines owing to the incidence of several infectious viruses such as coronavirus and hepatitis B will uplift the market potential during the forecast period, states Fortune Business Insights, in a report, titled “Recombinant Vaccines Market Size, Share & COVID-19 Impact Analysis, By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus (HPV), Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2020-2027.” The market size stood at USD 10.82 billion in 2019.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/recombinant-vaccines-market-101935
The report recombinant vaccines market comprises:
- Thorough report of the market
- Superior insights into the market
- Market drivers and restraints
- Regional analysis with valuable insights
- COVID-19 effect on recombinant vaccines
Market Driver:
Development of Novel Vaccines by Significant Players to Augment Growth
The growing prevalence of diseases and viruses has led to huge investments in R&D for the development of innovative drugs and vaccines. The production of vaccines in larger quantities to relieve the population and prevent the risk of vaccine unavailability. The rising focus of key players towards advanced DNA technology, genomics, and other biotechnology techniques can further enhance the production and thus, benefit the market effectively.
Furthermore, the stellar sales of novel products will subsequently boost the growth of the market. For instance, Merck’s Gardasil sales sprouted to US$ 3.7 billion in 2019 from US$ 1.7 billion in 2014. The vast majority of the population affected by Hepatitis B is predicted to be an essential factor in promoting the expansion of the market. As per the Hepatitis B Foundation, every year 30 million people are infected by the hepatitis B virus. Besides, the rising government initiatives and immunization programs will certainly create opportunities for the market in the forthcoming years.
The coronavirus emergency has given immense loss to industries and sectors across the globe. The governments of several countries have instigated lockdown to thwart the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain. But, with time and resolution, we will be able to combat this stern time and get back to normality. Our well-revised reports will help companies to receive in-depth information about the present scenario of every market so that you can adopt the necessary strategies accordingly.
To get to know more about the short-term and long-term impacts of COVID-19 on this market,
please visit: https://www.fortunebusinessinsights.com/industry-reports/recombinant-vaccines-market-101935
Heavy Demand for Vaccines to Escalate Business During Coronavirus
The growing demand for immunization drugs and vaccines due to the extensive spread of the disease amid coronavirus will improve the prospects of the market. The enormous R&D spending by industry players to develop recombinant COVID-19 vaccine will enable speedy expansion of the market in the forthcoming years. For instance, Novavax, a pipeline candidate NVX-CoV2373 is in the phase-1 clinical study against COVID-19. The ongoing clinal trials by pharmaceutical giants for the introduction of an effective COVID vaccine will accelerate the market revenue in the foreseeable future.
Regional Analysis:
Rapid Adoption of Effective Vaccines to Propel Market in North America
The market in North America stood at USD 4.97 billion in 2019 and is expected to rise excellently during the forecast period. The growth in the region is attributed to growing R&D investments by eminent players. The rapid adoption of efficient recombinant vaccines in the US. The increasing accessibility of advanced molecular & genetic engineering instruments is likely to improve the prospects of the market. Asia Pacific is expected to expand rapidly during the forecast period due to the immunization programs by governments.
The increasing demand for effective vaccines is likely to support the development of the market. The rising cases of human papillomavirus disease and hepatitis B are expected to spur opportunities for the market in the foreseeable future. According to the HPV Information Center in 2019, 106,430 annual incidences of human papillomavirus was recorded in China alone. The growing need for vaccine supply can be a crucial factor bolstering the growth of the market in Asia Pacific.
Quick Buy - Recombinant Vaccines Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101935
Important Development:
April 2020: AstraZeneca announced that it has collaborated with the University of Oxford for the development and distribution of recombinant adenovirus vaccine indicated against COVID-19 infection.
List of the Leading Companies Operating in the Recombinant Vaccines Market are:
- GlaxoSmithKline plc. (U.K, Europe)
- Merck & Co., Inc (New Jersey, U.S)
- Dynavax Technologies (California, U.S)
- Pfizer Inc (New York, U.S)
- Sanofi S.A (France, Europe)
- Serum Institute of India Pvt. Ltd (India, Asia Pacific)
- Novartis AG (Switzerland, Europe)
- Other Prominent Players
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/recombinant-vaccines-market-101935
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- New Product Launch
- Pipeline Analysis
- Technological Advancements in the Recombinant Vaccines Market
- Prevalence of Key Diseases- For Key Countries, 2019
- Key Industry Developments - Mergers, Acquisitions, and Partnerships
- Global Recombinant Vaccines Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Type
- Subunit
- Live Attenuated
- Market Analysis, Insights and Forecast – By Route of Administration
- Parenteral
- Oral
- Market Analysis, Insights and Forecast – By Disease Indication
- Human Papillomavirus
- Hepatitis B
- Rotavirus
- Herpes Zoster
- Meningococcal B
- Others
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
- Market Analysis, Insights and Forecast – By Geography
- North America
- Europe
- Asia pacific
- Latin America
- Middle East & Africa
Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/recombinant-vaccines-market-101935
Have a Look at Related Reports:
Vaccines Market Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026
Human Papillomavirus (HPV) Vaccines Market Share & Industry Analysis, By Type (Bivalent and Polyvalent), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) and Geography Forecast, 2019-2026
Influenza Vaccine Market Share & Industry Analysis, By Type (Inactivated and Live Attenuated), By Valency (Quadrivalent and Trivalent), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2019-2026
Pediatric Drugs and Vaccines Market Share and Global Trend By Product (Vaccines, Drugs) By Disease Indication (Infectious Disease, Cancer, Allergy And Respiratory, Nervous System Disorders, Cardiovascular Disease, Diabetes, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026
Recombinant DNA Technology Market Share and Global Trend By Product (Vaccines, Therapeutic Agents, Recombinant Protein, Others), By Component (Vectors, Expression System, Others), By Application (Diagnostics, Therapeutic, Food and Agriculture, Others), By End User (Biotechnology and Pharmaceutical Companies, Diagnostic Laboratories, Academic and Government Research Institutes, Other) and Geography Forecast till 2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/recombinant-vaccines-market-9498